

David J Brooks

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8427021/david-j-brooks-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330 papers	36,476 citations	94 h-index	185 g-index
373 ext. papers	41,823 ext. citations	7.8 avg, IF	7 L-index

#	Paper	IF	Citations
330	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 388-405	24.1	2760
329	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , 2000 , 342, 1484-91	59.2	1253
328	Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. <i>Nature Medicine</i> , 2003 , 9, 589-95	50.5	1095
327	In-vivo measurement of activated microglia in dementia. <i>Lancet, The</i> , 2001 , 358, 461-7	40	861
326	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
325	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. <i>Neurobiology of Disease</i> , 2006 , 21, 404-12	7.5	806
324	Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. <i>Human Brain Mapping</i> , 2003 , 19, 224-47	5.9	797
323	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011 , 95, 629-35	10.9	793
322	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006 , 59, 459-66	9.4	785
321	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. <i>Brain</i> , 2005 , 128, 1314-22	11.2	757
320	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
319	Core assessment program for intracerebral transplantations (CAPIT). <i>Movement Disorders</i> , 1992 , 7, 2-13	7	683
318	Inflammation after trauma: microglial activation and traumatic brain injury. <i>Annals of Neurology</i> , 2011 , 70, 374-83	9.4	623
317	11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology, The</i> , 2010 , 9, 363-72	24.1	589
316	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. <i>Nature Neuroscience</i> , 1999 , 2, 1137-40	25.5	582
315	18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. <i>Annals of Neurology</i> , 2010 , 68, 319-29	9.4	475
314	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PiB-PET study. <i>Neurobiology of Disease</i> , 2008 , 32, 412-9	7.5	395

313	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1939-49	27.4	379
312	Dyskinesias following neural transplantation in Parkinson's disease. <i>Nature Neuroscience</i> , 2002 , 5, 627-8	25.5	365
311	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , 2006 , 59, 852-8	9.4	359
310	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. <i>Annals of Neurology</i> , 1994 , 35, 172-80	9.4	326
309	Microglial activation in presymptomatic Huntington's disease gene carriers. <i>Brain</i> , 2007 , 130, 1759-66	11.2	324
308	Mapping the network for planning: a correlational PET activation study with the Tower of London task. <i>Brain</i> , 1999 , 122 (Pt 10), 1973-87	11.2	311
307	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology, The</i> , 2012 , 11, 241-9	24.1	307
306	Identification of the cerebral loci processing human swallowing with H2(15)O PET activation. <i>Journal of Neurophysiology</i> , 1999 , 81, 1917-26	3.2	291
305	Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. <i>Neurology</i> , 2014 , 82, 308-16	6.5	288
304	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. <i>Archives of Neurology</i> , 2012 , 69, 198-207		288
303	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. <i>Brain</i> , 2005 , 128, 2786-96	11.2	283
302	The spectrum of nonmotor symptoms in early Parkinson disease. <i>Neurology</i> , 2013 , 80, 276-81	6.5	281
301	Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. <i>Annals of Neurology</i> , 1992 , 31, 166-73	9.4	279
300	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <i>Annals of Neurology</i> , 1997 , 42, 95-107	9.4	276
299	The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. <i>Annals of Neurology</i> , 1999 , 45, 577-82	9.4	275
298	The human premotor cortex is 'mirror' only for biological actions. <i>Current Biology</i> , 2004 , 14, 117-20	6.3	259
297	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β amyloid 42: a cross-validation study against amyloid positron emission tomography. <i>JAMA Neurology</i> , 2014 , 71, 1282-9	17.2	254
296	Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. <i>Lancet, The</i> , 1999 , 353, 1662-7	4.0	246

295	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 655-61	7	245
294	Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. <i>Movement Disorders</i> , 1998 , 13, 39-45	7	234
293	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. <i>Science Translational Medicine</i> , 2010 , 2, 38ra46	17.5	231
292	Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1251-9	8.9	231
291	Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. <i>Nature Medicine</i> , 2005 , 11, 703-4	50.5	225
290	Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. <i>Movement Disorders</i> , 2014 , 29, 195-202	7	224
289	Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. <i>Brain</i> , 2010 , 133, 3434-43	11.2	224
288	Increased dopamine tone during meditation-induced change of consciousness. <i>Cognitive Brain Research</i> , 2002 , 13, 255-9		222
287	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , 2000 , 48, 689-695	9.4	211
286	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. <i>Brain</i> , 2005 , 128, 2977-86	11.2	205
285	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. <i>Brain</i> , 2008 , 131, 1294-302	11.2	204
284	Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. <i>Synapse</i> , 1992 , 12, 47-54	2.4	183
283	Huntington's disease progression. PET and clinical observations. <i>Brain</i> , 1999 , 122 (Pt 12), 2353-63	11.2	181
282	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. <i>Brain</i> , 2003 , 126, 1127-35	11.2	180
281	Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010 , 40, 216-21	7.5	179
280	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <i>Annals of Neurology</i> , 2002 , 52, 849-53	9.4	179
279	Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 818-22	8.9	175
278	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , 2013 , 81, 487-500	6.5	173

277	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1340-9	15.9	172
276	Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. <i>Annals of Neurology</i> , 2006 , 60, 145-7	9.4	163
275	Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. <i>Neuropsychopharmacology</i> , 2013 , 38, 938-49	8.7	158
274	Age at onset and Parkinson disease phenotype. <i>Neurology</i> , 2016 , 86, 1400-1407	6.5	157
273	An early and late peak in microglial activation in Alzheimer's disease trajectory. <i>Brain</i> , 2017 , 140, 792-803	11.2	156
272	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012 , 259, 1639-47	5.5	153
271	Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. <i>Brain</i> , 2011 , 134, 979-86	11.2	152
270	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 104-14	8.8	148
269	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. <i>Human Brain Mapping</i> , 2011 , 32, 258-70	5.9	147
268	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2015 , 138, 2974-86	11.2	146
267	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. <i>Movement Disorders</i> , 2006 , 21, 89-93	7	144
266	Imaging approaches to Parkinson disease. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 596-609	8.9	139
265	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C](R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010 , 25, 97-107	7	136
264	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 53, 647-53	9.4	136
263	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. <i>Lancet Neurology</i> , 2018 , 17, 618-628	24.1	135
262	Imaging biomarkers in Parkinson's disease. <i>Progress in Neurobiology</i> , 2011 , 95, 614-28	10.9	134
261	Plasticity of the nigropallidal pathway in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 53, 206-13	9.4	132
260	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. <i>Neuropsychologia</i> , 2007 , 45, 65-74	3.2	130

259	Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. <i>Brain</i> , 2020 , 143, 3077-3088	11.2	130
258	Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. <i>Movement Disorders</i> , 2011 , 26, 1997-2003	7	126
257	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. <i>Alzheimer's and Dementia</i> , 2015 , 11, 608-21.e7	1.2	121
256	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. <i>Brain</i> , 2002 , 125, 2248-56	11.2	120
255	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. <i>Movement Disorders</i> , 2009 , 24, 949-64	7	119
254	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. <i>Movement Disorders</i> , 2004 , 19, 1221-6	7	117
253	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006 , 21, 1844-50	11.2	116
252	Imaging in Parkinson's disease: the role of monoamines in behavior. <i>Biological Psychiatry</i> , 2006 , 59, 908-18	7.9	116
251	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. <i>Movement Disorders</i> , 1998 , 13, 46-51	7	115
250	The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. <i>Brain</i> , 2005 , 128, 906-17	11.2	114
249	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2014 , 137, 2743-58	11.2	109
248	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. <i>Brain</i> , 2017 , 140, 2002-2011	11.2	105
247	Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. <i>NeuroImage</i> , 2011 , 56, 1463-8	7.9	105
246	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. <i>Brain</i> , 2015 , 138, 653-63	11.2	103
245	Imaging microglial activation in Huntington's disease. <i>Brain Research Bulletin</i> , 2007 , 72, 148-51	3.9	103
244	GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1030-5	8.9	101
243	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. <i>Lancet Neurology</i> , 2017 , 16, 789-796	24.1	98
242	Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. <i>Neurobiology of Disease</i> , 2008 , 29, 381-90	7.5	96

241	Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. <i>British Journal of Psychiatry</i> , 1998 , 172, 316-23	5.4	96
240	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. <i>Aids</i> , 2014 , 28, 67-72	3.5	95
239	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , 2020 , 19, 951-962	24.1	95
238	In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. <i>Brain</i> , 2016 , 139, 2039-49	11.2	95
237	Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. <i>Movement Disorders</i> , 2001 , 16, 1014-22	7	94
236	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
235	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. <i>Brain</i> , 2018 , 141, 2740-2754	11.2	93
234	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. <i>Science Translational Medicine</i> , 2012 , 4, 128ra41	17.5	92
233	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. <i>Brain</i> , 2004 , 127, 1332-42	11.2	92
232	Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. <i>Synapse</i> , 1995 , 21, 45-53	2.4	89
231	Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. <i>Movement Disorders</i> , 1998 , 13, 309-18	7	87
230	Amyloid pathology and axonal injury after brain trauma. <i>Neurology</i> , 2016 , 86, 821-8	6.5	86
229	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. <i>Synapse</i> , 2002 , 43, 201-7	2.4	86
228	Imaging neurodegeneration in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009 , 1792, 722-9	6.9	85
227	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. <i>NeuroRx</i> , 2005 , 2, 226-36		85
226	Dopamine agonists and neuroprotection in Parkinson's disease. <i>Annals of Neurology</i> , 1998 , 44, S167-74	9.4	85
225	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. <i>Experimental Neurology</i> , 2008 , 214, 112-6	5.7	84
224	Upregulation of opioid receptor binding following spontaneous epileptic seizures. <i>Brain</i> , 2007 , 130, 1009-16	11.6	84

223	Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. <i>NeuroImage</i> , 2007 , 38, 261-70	7.9	84
222	Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 3685-98	11.2	82
221	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. <i>Brain</i> , 2003 , 126, 312-25	11.2	81
220	Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. <i>Brain</i> , 2018 , 141, 496-504	11.2	80
219	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. <i>Hippocampus</i> , 1999 , 9, 247-54	3.5	80
218	The effect of movement frequency on cerebral activation: a positron emission tomography study. <i>Journal of the Neurological Sciences</i> , 1997 , 151, 195-205	3.2	79
217	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. <i>Neurology</i> , 2013 , 80, 1850-5	6.5	76
216	Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1753-1759	8.9	75
215	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. <i>Brain</i> , 2011 , 134, 293-300	11.2	75
214	Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. <i>Epilepsia</i> , 1997 , 38, 1089-97	6.4	75
213	The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 657-65	5.5	73
212	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. <i>PLoS ONE</i> , 2013 , 8, e57221	3.7	73
211	Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 1249-56	8.9	73
210	Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 39-47	3.1	73
209	Implementation and application of a brain template for multiple volumes of interest. <i>Human Brain Mapping</i> , 2002 , 15, 165-74	5.9	73
208	Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1984 , 4, 535-45	7.3	73
207	Neuroimaging in Parkinson's disease. <i>NeuroRx</i> , 2004 , 1, 243-54		72
206	Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. <i>Brain Research</i> , 2003 , 982, 137-45	3.7	71

205	Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. <i>Brain</i> , 2003 , 126, 1300-18	11.2	70
204	Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. <i>Movement Disorders</i> , 2009 , 24 Suppl 2, S742-7	7	69
203	11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997 , 17, 943-9	7.3	68
202	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 825-31	5.5	68
201	Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. <i>Journal of Parkinson's Disease</i> , 2013 , 3, 1-11	5.3	67
200	Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shunting--A retrospective analysis of [(15)O]H(2)O PET-CBF studies in 65 patients. <i>Clinical Neurology and Neurosurgery</i> , 2008 , 110, 369-75	2	64
199	A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1990 , 10, 307-16	7.3	64
198	Molecular imaging of dopamine transporters. <i>Ageing Research Reviews</i> , 2016 , 30, 114-21	12	61
197	STN stimulation alters pallidal-frontal coupling during response selection under competition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007 , 27, 1173-84	7.3	59
196	Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 423-30	8.9	58
195	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. <i>European Neuropsychopharmacology</i> , 2009 , 19, 740-8	1.2	58
194	Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. <i>British Journal of Psychiatry</i> , 2007 , 191, 63-9	5.4	58
193	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). <i>Trials</i> , 2019 , 20, 191	2.8	57
192	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1885-1912	8.8	57
191	Kinetic analysis of the translocator protein positron emission tomography ligand [F]GE-180 in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 2201-2210	8.8	57
190	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1110-20	1.2	57
189	Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 309-15	4.7	57
188	Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. <i>Movement Disorders</i> , 2018 , 33, 909-919	7	56

187	In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 618-26	9.4	55
186	Decreased intestinal acetylcholinesterase in early Parkinson disease: An C-donepezil PET study. <i>Neurology</i> , 2017 , 88, 775-781	6.5	54
185	Stereotactic thalamotomy in tremor-dominant Parkinson's disease: an H2(15)O PET motor activation study. <i>Annals of Neurology</i> , 1997 , 41, 108-11	9.4	54
184	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , 2008 , 193, 65-72	5.4	53
183	Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. <i>Human Brain Mapping</i> , 2007 , 28, 34-48	5.9	53
182	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. <i>Brain</i> , 2012 , 135, 2449-57	11.2	52
181	Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. <i>Neurodegenerative Diseases</i> , 2012 , 10, 246-9	2.3	51
180	The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999 , 19, 673-8	7.3	51
179	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2010 , 37, 356-61	7.5	49
178	What can biomarkers tell us about cognition in Parkinson's disease?. <i>Movement Disorders</i> , 2014 , 29, 622-33	3.3	48
177	Safety and tolerability of COMT inhibitors. <i>Neurology</i> , 2004 , 62, S39-46	6.5	48
176	Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. <i>Movement Disorders</i> , 1997 , 12, 691-6	7	47
175	Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. <i>Annals of Neurology</i> , 1994 , 35, 298-303	9.4	47
174	L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. <i>Movement Disorders</i> , 1995 , 10, 241-9	7	47
173	Measurement of regional cerebral pH in human subjects using continuous inhalation of 11CO2 and positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1984 , 4, 458-65	7.3	47
172	The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study. <i>Journal of Neuroinflammation</i> , 2020 , 17, 151	10.1	45
171	An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. <i>Clinical Neuropharmacology</i> , 2010 , 33, 55-60	1.4	44
170	A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. <i>Metabolic Brain Disease</i> , 1999 , 14, 45-55	3.9	44

169	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. <i>Biological Psychiatry</i> , 2004 , 55, 904-15	7.9	43
168	Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. <i>Neurology</i> , 2013 , 81, 1176-8	6.5	42
167	Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. <i>Annals of Neurology</i> , 2005 , 57, 634-41	9.4	42
166	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008 , 9, 43-9		41
165	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [(11C)diprenorphine test-retest data. <i>NeuroImage</i> , 2007 , 38, 82-94	7.9	41
164	Benzodiazepine-GABAA receptors in idiopathic generalized epilepsy measured with [11C]flumazenil and positron emission tomography. <i>Epilepsia</i> , 1995 , 36, 113-21	6.4	41
163	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 224-9	7	40
162	Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 1275-89	4.3	40
161	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. <i>Neurology</i> , 2019 , 92, e1331-e1343	6.5	39
160	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015 , 36, 1736-1742	5.6	39
159	Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. <i>Journal of Neuroinflammation</i> , 2015 , 12, 224	10.1	39
158	A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced benzodiazepine receptors in limbic regions. <i>Journal of Psychopharmacology</i> , 2012 , 26, 273-81	4.6	39
157	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2007 , 8, 343-7		39
156	Imaging end points for monitoring neuroprotection in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 53 Suppl 3, S110-8; discussion S118-9	9.4	39
155	Parkinson's disease: diagnosis. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S31-3	3.6	38
154	Reward processing in health and Parkinson's disease: neural organization and reorganization. <i>Cerebral Cortex</i> , 2004 , 14, 73-80	5.1	38
153	Binary classification of 18 F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. <i>NeuroImage</i> , 2013 , 64, 517-25	7.9	37
152	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([F]-AV-1451) Binding. <i>Molecular Imaging and Biology</i> , 2018 , 20, 356-360	3.8	37

151	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β -positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
150	Serotonergic mediated body mass index changes in Parkinson's disease. <i>Neurobiology of Disease</i> , 2011 , 43, 609-15	7.5	36
149	Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. <i>Movement Disorders</i> , 2009 , 24, 2260-6	7	36
148	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1062-6	7	36
147	In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: dosimetry, biodistribution, and kinetic analyses. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1818-24	8.9	35
146	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. <i>Neurobiology of Disease</i> , 2018 , 117, 211-216	7.5	34
145	Apathy blunts neural response to money in Parkinson's disease. <i>Social Neuroscience</i> , 2011 , 6, 653-62	2	33
144	Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. <i>Trends in Molecular Medicine</i> , 1998 , 4, 532-9		33
143	Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. <i>Journal of Neurology</i> , 2007 , 254, 1033-6	5.5	33
142	A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. <i>NeuroImage</i> , 2007 , 36, 28-37	7.9	33
141	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. <i>Movement Disorders</i> , 2017 , 32, 922-927	7	32
140	Parkinsonism associated with acute intracranial hematomas: an [18F]dopa positron-emission tomography study. <i>Movement Disorders</i> , 1997 , 12, 1035-8	7	32
139	Imaging non-dopaminergic function in Parkinson's disease. <i>Molecular Imaging and Biology</i> , 2007 , 9, 217-228	3	32
138	New developments of brain imaging for Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2006 , 21, 2035-41	7	31
137	PET studies on the function of dopamine in health and Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2003 , 991, 22-35	6.5	31
136	Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. <i>Epilepsia</i> , 2005 , 46, 944-8	6.4	31
135	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , 2017 , 55, 78-90	5.6	30
134	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , 2016 , 87, 2451-2456	6.5	30

133	Brain monoamine systems in multiple system atrophy: a positron emission tomography study. <i>Neurobiology of Disease</i> , 2012 , 46, 130-6	7.5	30
132	Imaging dopamine transporters in Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010 , 4, 651-60	2.3	30
131	[11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008 , 28, 207-16	7.3	30
130	Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2017 , 38, 1702-1715	5.9	29
129	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology, The</i> , 2006 , 5, 200-2	24.1	29
128	Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. <i>Neuropsychologia</i> , 2004 , 42, 1917-26	3.2	29
127	Technology insight: imaging neurodegeneration in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2008 , 4, 267-77		28
126	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. <i>Molecular Imaging and Biology</i> , 2019 , 21, 935-944	3.8	27
125	Dynamic C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1452-1460	8.9	27
124	Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. <i>PLoS ONE</i> , 2012 , 7, e38980	3.7	27
123	Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. <i>Movement Disorders</i> , 2006 , 21, 783-8	7	27
122	Chorea associated with thyroxine replacement therapy. <i>Movement Disorders</i> , 2005 , 20, 1656-7	7	27
121	Benzodiazepine-GABAA receptor binding during absence seizures. <i>Epilepsia</i> , 1995 , 36, 592-9	6.4	27
120	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 707-13	8.9	26
119	The prognostic value of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1207-19	8.8	26
118	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , 2000 , 15, 446-458	7	26
117	Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology</i> , 2018 , 265, 1528-1539	5.5	24
116	Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017 , 16, 455-460	5.3	24

115	Characterisation of the contribution of the GABA-benzodiazepine α receptor subtype to [(11)C]Ro15-4513 PET images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 731-44	7.3	24
114	Imaging basal ganglia function. <i>Journal of Anatomy</i> , 2000 , 196 (Pt 4), 543-54	2.9	24
113	Diagnosis and management of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 72 Suppl 1, I10-I16	5.5	24
112	Imaging synucleinopathies. <i>Movement Disorders</i> , 2016 , 31, 814-29	7	24
111	Imaging biomarkers in tauopathies. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S26-8	3.6	22
110	In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. <i>Experimental Neurology</i> , 2010 , 222, 120-4	5.7	22
109	Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 564-568	7	21
108	Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study. <i>Neuropsychopharmacology</i> , 2011 , 36, 735-43	8.7	21
107	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. <i>NeuroImage</i> , 2009 , 48, 329-38	7.9	21
106	Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2008 , 115, 843-9	4.3	21
105	Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. <i>Experimental Neurology</i> , 2018 , 303, 142-152	5.7	20
104	Imaging non-motor aspects of Parkinson's disease. <i>Progress in Brain Research</i> , 2010 , 184, 205-18	2.9	20
103	Parametric mapping using spectral analysis for C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1432-1441	8.8	19
102	Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. <i>Addiction Biology</i> , 2014 , 19, 1032-40	4.6	19
101	Examining Braak's hypothesis by imaging Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S83-8	7	19
100	Updated guidelines for the management of Parkinson's disease. <i>British Journal of Hospital Medicine</i> , 2001 , 62, 456-70		19
99	Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease. <i>Movement Disorders</i> , 2021 , 36, 774-779	7	19
98	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. <i>Movement Disorders</i> , 2018 , 33, 1006-1010	7	19

97	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. <i>Neurobiology of Disease</i> , 2018 , 115, 9-16	7.5	18
96	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. <i>Frontiers in Behavioral Neuroscience</i> , 2014 , 8, 86	3.5	18
95	Reference region automatic extraction in dynamic [(11)C]PIB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 1725-31	7.3	18
94	Assessment of Parkinson's disease with imaging. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S268-75	3.6	18
93	The Future of Brain Imaging in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, S47-S51	5.3	18
92	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 527-32	3.6	17
91	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 299-305	7	17
90	Positron emission tomography imaging of transplant function. <i>NeuroRx</i> , 2004 , 1, 482-91		17
89	Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. <i>Nuclear Medicine and Biology</i> , 1996 , 23, 377-84	2.1	17
88	Role of Neuroinflammation in the Trajectory of Alzheimer's Disease and in vivo Quantification Using PET. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S339-S351	4.3	17
87	Imaging Systemic Dysfunction in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016 , 16, 51	6.6	16
86	Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. <i>NeuroImage</i> , 2014 , 97, 151-62	7.9	15
85	Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. <i>Frontiers in Psychology</i> , 2013 , 4, 90	3.4	15
84	The role of structural and functional imaging in parkinsonian states with a description of PET technology. <i>Seminars in Neurology</i> , 2008 , 28, 435-45	3.2	15
83	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017 , 32, 235-240	7	14
82	Quantification of opioid receptor availability following spontaneous epileptic seizures: correction of [11C]diprenorphine PET data for the partial-volume effect. <i>NeuroImage</i> , 2013 , 79, 72-80	7.9	14
81	Dopaminergic action beyond its effects on motor function: imaging studies. <i>Journal of Neurology</i> , 2006 , 253 Suppl 4, IV8-15	5.5	14
80	Opioid binding in DYT1 primary torsion dystonia: an 11C-diprenorphine PET study. <i>Movement Disorders</i> , 2004 , 19, 1498-503	7	14

79	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. <i>Neurobiology of Disease</i> , 2021 , 149, 105229	7.5	14
78	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 47	9	14
77	An imaging study of parkinsonism among African-Caribbean and Indian London communities. <i>Movement Disorders</i> , 2002 , 17, 1321-8	7	13
76	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
75	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2018 , 2018, 6852303	3.7	13
74	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 743-7	5.3	12
73	Progression of sleep disturbances in Parkinson's disease: a 5-year longitudinal study. <i>Journal of Neurology</i> , 2021 , 268, 312-320	5.5	12
72	Attenuation of dopamine-induced GABA release in problem gamblers. <i>Brain and Behavior</i> , 2019 , 9, e012394	3.4	10
71	Cardiovascular effects of methamphetamine in Parkinson's disease patients. <i>Movement Disorders</i> , 2004 , 19, 298-303	7	10
70	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 3	9	10
69	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [C]UCB-J PET Imaging Study. <i>Movement Disorders</i> , 2021 , 36, 2057-2065	7	10
68	Comment on "In Vivo [F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". <i>ACS Chemical Neuroscience</i> , 2019 , 10, 768-772	5.7	10
67	The Cholinergic Brain in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1012-1026	2.2	10
66	Imaging Parkinson's disease below the neck. <i>Npj Parkinson's Disease</i> , 2017 , 3, 15	9.7	9
65	In vivo quantification of glial activation in minipigs overexpressing human α -synuclein. <i>Synapse</i> , 2018 , 72, e22060	2.4	9
64	Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. <i>Journal of Neurology</i> , 2007 , 254, IV37-IV48	5.5	9
63	The clinical role of PET in cerebrovascular disease. <i>Neurosurgical Review</i> , 1991 , 14, 91-6	3.9	9
62	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9

61	In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 819-830	7.3	9
60	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder - A PET study. <i>Parkinsonism and Related Disorders</i> , 2020 , 75, 63-69	3.6	8
59	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. <i>Clinical Neurophysiology</i> , 2018 , 129, 541-547	4.3	8
58	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 15758	4.9	8
57	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 340-1	5.5	8
56	Positron emission tomography in the study of cerebral tumours. <i>Neurosurgical Review</i> , 1984 , 7, 253-8	3.9	8
55	NMDA receptor ion channel activation detected in vivo with [F]GE-179 PET after electrical stimulation of rat hippocampus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1301-1312	7.3	8
54	Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold. <i>Journal of Neuroimaging</i> , 2019 , 29, 499-505	2.8	7
53	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. <i>Journal of Neurology</i> , 2020 , 267, 2296-2300	5.5	7
52	Milestones in neuroimaging. <i>Movement Disorders</i> , 2011 , 26, 868-978	7	7
51	Technical aspects of amyloid imaging for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011 , 3, 25	9	7
50	Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. <i>Wiener Klinische Wochenschrift</i> , 2006 , 118, 570-2	2.3	7
49	Using [(11C)Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. <i>NeuroImage</i> , 2016 , 132, 1-7	7.9	7
48	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1677-1687	5.3	7
47	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. <i>Brain</i> , 2021 , 144, 2732-2744	11.2	7
46	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 327-332	5.2	6
45	The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1693-4	8.8	6
44	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. <i>Movement Disorders</i> , 2001 , 16, 382-395	7	6

43	Recent imaging advances in the diagnosis and management of Parkinson's disease. <i>F1000 Medicine Reports</i> , 2009 , 1,		6
42	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2020 , 81, 89-93	3.6	6
41	Impaired perfusion and capillary dysfunction in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12032	5.2	5
40	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
39	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2242-2243	8.8	3
38	Preclinical PET Studies of [C]UCB-J Binding in Minipig Brain. <i>Molecular Imaging and Biology</i> , 2020 , 22, 1290-1300	3.8	3
37	Imaging of genetic and degenerative disorders primarily causing Parkinsonism. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 135, 493-505	3	3
36	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 161-171	5.3	3
35	Simplifying [F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. <i>EJNMMI Research</i> , 2018 , 8, 46	3.6	3
34	Non-invasive in vivo imaging of transplant function. <i>Progress in Brain Research</i> , 2000 , 127, 321-32	2.9	2
33	Towards improved test-retest reliability in quantitative ligand PET: [11C]Diprenorphine as an example. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S665-S665	7.3	2
32	Tauopathy in the APP ^{swe} /PS1 ^{E9} mouse model of familial Alzheimer's disease		2
31	In Response to Letter from Fregonara et al. 2019. <i>Molecular Imaging and Biology</i> , 2020 , 22, 13-14	3.8	2
30	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. <i>Neurobiology of Disease</i> , 2021 , 152, 105295	7.5	2
29	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , 2021 , 90, 52-56	3.6	2
28	[P2197]: AMYLOID DEPOSITION, TAU AGGREGATION AND MICROGLIAL ACTIVATION CORRELATE WITH VASCULAR BURDEN IN VIVO IN ALZHEIMER'S DISEASE 2017 , 13, P681-P682		1
27	[O1201]: [18F]FLUTEMETAMOL AMYLOID SCANNING IN A PHASE III AMNESTIC MILD COGNITIVE IMPAIRMENT STUDY: ADDITIONAL INFLUENCE OF OTHER BIOMARKERS IN ESTIMATING RISK OF CONVERSION TO PROBABLE ALZHEIMER'S DISEASE 2017 , 13, P221		1
26	Bad news for neuroprotective therapies in PD?. <i>Journal of Parkinson's Disease</i> , 2013 , 3, 271-3	5.3	1

25	Imaging studies in drug development: Parkinson's disease. <i>Drug Discovery Today: Technologies</i> , 2005 , 2, 317-21	7.1	1
24	Global Increase in Cortical Opioid Binding Potential with Aging: In Vivo Quantification with ¹¹ C diprenorphine PET. <i>Psychogeriatrics</i> , 2001 , 1, 309-316	1.8	1
23	PET: Motor function and dysfunction. <i>Movement Disorders</i> , 1992 , 7, 20-20	7	1
22	PET Imaging of Translocator Protein Expression in Neurological Disorders 2021 , 1021-1040		1
21	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. <i>Brain</i> , 2021 , 144, 1498-1508	1.2	1
20	Future Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 303-308	5.4	1
19	Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism. <i>Neurotherapeutics</i> , 2021 , 18, 753-771	6.4	1
18	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology 1999 , 9, 247		1
17	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [¹⁸ F]FEOBV PET/CT study.. <i>EJNMMI Research</i> , 2022 , 12, 17	3.6	1
16	Activated N-methyl-D-aspartate receptor ion channels detected in focal epilepsy with [¹⁸ F]GE-179 positron emission tomography. <i>Epilepsia</i> , 2021 , 62, 2899-2908	6.4	0
15	Capillary function progressively deteriorates in prodromal Alzheimer's disease: A longitudinal MRI perfusion study. <i>Aging Brain</i> , 2022 , 2, 100035		0
14	Microglial activation evaluated using flutriciclamide (¹¹ F-GE180) in subjects with cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045465	1.2	
13	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046045	1.2	
12	[P1030]: DIFFERENT MODELLING APPROACHES FOR TAU TRACER ¹⁸ F-AV1451 IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE 2017 , 13, P291-P292		
11	[P4065]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL 2017 , 13, P1385-P1385		
10	[IC-P-074]: LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAINS DECLINE IN EARLY STAGE PARKINSON'S DISEASE: ICICLE-PD STUDY 2017 , 13, P61-P61		
9	[IC-P-088]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL 2017 , 13, P71-P72		
8	Imaging Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 245-63	3	

7	Reply: Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1522-1522	7
6	Neuroimaging in Parkinson's disease. <i>Neurotherapeutics</i> , 2004 , 1, 243-254	6.4
5	Positron emission tomography imaging of transplant function. <i>Neurotherapeutics</i> , 2004 , 1, 482-491	6.4
4	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. <i>Neurotherapeutics</i> , 2005 , 2, 226-236	6.4
3	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S591-S591	7.3
2	Influence of microglial activation on structural and functional connectivity in mild cognitive impairment subjects. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042990	1.2
1	Neuroinflammation, functional connectivity and structural network integrity in the Alzheimer's spectrum.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055970	1.2